Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 30;11(4):769.
doi: 10.3390/vaccines11040769.

Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines

Affiliations
Review

Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines

Christoph Jindra et al. Vaccines (Basel). .

Abstract

Horses and other equid species are frequently affected by bovine papillomavirus type 1 and/or 2 (BPV1, BPV2)-induced skin tumors termed sarcoids. Although sarcoids do not metastasize, they constitute a serious health problem due to their BPV1/2-mediated resistance to treatment and propensity to recrudesce in a more severe, multiple form following accidental or iatrogenic trauma. This review provides an overview on BPV1/2 infection and associated immune escape in the equid host and presents early and recent immunotherapeutic approaches in sarcoid management.

Keywords: BPV1; BPV2; bovine papillomavirus; equids; horse; immunotherapy; sarcoid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The productive PV life cycle is tightly linked to the differentiation program of infected keratinocytes.
Figure 2
Figure 2
Role of Toll-like receptors in T cell activation. Recognition of PAMPs by TLRs expressed by dendritic cells (DCs) leads to maturation of these antigen-presenting cells and their migration to draining lymph nodes. In the presence of co-stimulatory molecules, DCs present antigens via MHC molecules to naive T cells. Upon this stimulus, naive T cells differentiate into effector T cells that expand, move to the site of infection, and fight the invading pathogens [65,66].
Figure 3
Figure 3
Influence of clinical sarcoid types on response to immunotherapy.

Similar articles

Cited by

References

    1. Knottenbelt D.C. A suggested clinical classification for the equine sarcoid. Clin. Tech. Equine Pract. 2005;4:278–295. doi: 10.1053/j.ctep.2005.10.008. - DOI
    1. Nasir L., Reid S.W.J. Papillomavirus Research: From Natural History to Vaccines and Beyond. Volume 1. Caister Academic Press; Norfolk, UK: 2006. Bovine papillomaviruses and equine sarcoids; pp. 389–397.
    1. Scott D.W., Miller W.H., Jr. Sarcoid. Equine Dermatol. 2003;1:719–731.
    1. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17–27. doi: 10.1016/j.virol.2004.03.033. - DOI - PubMed
    1. Campo M.S. Papillomavirus Research: From Natural History to Vaccines and Beyond. Caister Academic Press; Norfolk, UK: 2006. Introduction; pp. 1–2.

LinkOut - more resources